A carregar cotações...
Previsão
Não temos dados de analistas para esta empresa.
Discussões na comunidade
Ainda não há nenhuma discussão sobre este ativo.
Iniciar discussãoNotícias Ir para o feed de notícias
Tempus AI secures $1.1 billion in data contracts, shares rally
Tempus AI said it signed $1.1 billion in sealed data contracts with 70 customers in 2025, including major life-sciences firms such as AstraZeneca, Pfizer, Merck and Abbvie. The company reported revenue retention around 126% and called 2025 a record year for its Data and Applications business. Shares rose as much as 15% intraday and closed up 4.51% at $69.26. Tempus AI plans to finalize and report full 2025 financial results on an earnings call in February 2026. » Mais em finance.yahoo.com
Tempus AI raises FY25 guidance, cites FDA clearance and Paige acquisition as growth drivers
Tempus AI guided FY25 revenue to $1.25–$1.26 billion (about 81% YoY) and expects roughly $1.55 billion in FY26 revenue, valuing the company at ~9.16x 2026 sales. Recent catalysts include FDA clearance for its xR IVD product and the $81 million acquisition of Paige, which expand addressable markets and AI pathology capabilities. Analysts note strong revenue visibility and execution, while valuation appears supported by forward growth despite a trailing P/E around 41.5 and elevated share performance since April. » Mais em finance.yahoo.com
Tempus AI reaches all-time high of $98.14
Tempus AI stock climbed to an all-time high of $98.14, bringing market capitalization to about $16.16 billion. Analyst price targets range from $60 to $100; Guggenheim raised its target to $95 and H.C. Wainwright to $98. Tempus recorded revenue growth of 59.84% over the last twelve months and a 1-year performance of +96.54%. The company received FDA 510(k) clearance for the RNA-based diagnostic Tempus xR IVD and expanded its CARE program for breast cancer screening. » Mais em de.investing.com
ARK Invest increases stake in AMD and divests heavily from Tempus AI
Cathie Wood’s ARK ETFs bought 25,899 shares of Advanced Micro Devices through ARKF on September 16, worth about $4.17 million. At the same time, a total of 167,598 shares of Tempus AI were sold via ARKK and ARKG for roughly $14.27 million, part of an ongoing reallocation toward selected technology and biotech names. » Mais em de.investing.com
Cathie Woods' ARK ETFs sell Tempus AI and buy Arcturus
In the trading session on September 15, 2025, Cathie Woods' ARK ETFs adjusted their portfolios: via ARKG, 7,270 shares of Tempus AI were sold for $627,982, while 27,408 shares of Arcturus were purchased for $474,706. At the same time, ARK made buys in Bullish, eToro, Figma and Toast and sales of Kratos, Rocket Lab and Shopify. The transactions point to a strategic reshuffle within the fund's biotechnology and AI positions. » Mais em de.investing.com
Dividendos históricos Dividendos
Todos os indicadores de dividendos Todos os indicadoresDados financeiros da empresa
| (EUR) | junho de 2026 | YoY |
|---|---|---|
| Receitas | 73,2 mil | 2,72% |
| Ganho bruto | 36,96 mil | 2,92% |
| Ganho líquido | -34,56 mil | 11,85% |
| EBITDA | 2,21 mil | 243,99% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 2,81 mi |
Número de ações | 30,48 mi |
Máximo/mínimo de 52 semanas | € 0,0954 - € 0,0254 |
| Dividendos | Não |
Beta | -0,04 |
PER (PE Ratio) | -17,26 |
PEG (PEG Ratio) | 8,68 |
P/VC (PB Ratio) | 2,62 |
P/V (PS Ratio) | 8,96 |
Perfil da empresa
A Tempus Capital Inc. opera como uma empresa operacional imobiliária no Canadá. O portefólio imobiliário da empresa inclui quatro propriedades, compreendendo um centro comercial, uma propriedade comercial e duas propriedades mistas comerciais/residenciais, no Ontário. A Tempus Capital Inc. foi constituída em 2011 e tem sede em Burlington, Canadá.
| Nome | TEMPUS CAPITAL INC. |
| CEO | Russell Tanz |
| Sede | Burlington,
on Canadá |
| Site | |
| Indústria | Máquinas |
| Entrada em bolsa | 28/02/2019 |
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
Cnq | TEMP.CN |